2022
Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites
Bajaj J, Fischer J, Yeramian P, Gavis E, Fagan A, Angeli P, Garcia-Tsao G, Adams J, Markham P. Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites. GastroHep 2022, 2022: 1-8. DOI: 10.1155/2022/5065478.Peer-Reviewed Original ResearchLarge-volume paracentesesRefractory ascitesContinuous intravenous infusionIntravenous infusionAverage steady-state plasma concentrationTreatment-related adverse eventsSteady-state plasma concentrationsML/min/Efficacy of terlipressinInfusion of terlipressinSafety/tolerabilityAdvanced liver cirrhosisPhase 2a trialVolume of ascitesVolume of distributionState plasma concentrationsHepatorenal syndromeVariceal bleedingCirrhotic patientsInpatient periodAdverse eventsLiver cirrhosisIV infusionRelated complicationsAcceptable safety
2018
Ascites
Garcia‐Tsao G. Ascites. 2018, 127-150. DOI: 10.1002/9781119237662.ch9.Peer-Reviewed Educational MaterialsLarge-volume paracentesesHepatorenal syndromeRefractory ascitesCirrhotic ascitesCommon decompensating eventMassive hepatic metastasesPlasma renin activitySecond-line treatmentFormation of ascitesDevelopment of ascitesCost-effective treatmentSinusoidal hypertensionCardiac indexRenin activityVasodilatory stateHepatic metastasesMalignant ascitesAscites formationCommon precipitantsAscitesHigh mortalityBacterial infectionsHyponatremiaMain predictorsPatients